Iridium Radioisotopes
Radioisotopes
Zinc Radioisotopes
Hydrogenation
Allyl Compounds
Coordination Complexes
Minor Planets
Radioisotope Dilution Technique
Meteoroids
Phosphines
Strontium Radioisotopes
Alcohols
Rhodium
Iodine Radioisotopes
Three-year clinical and angiographic follow-up after intracoronary radiation : results of a randomized clinical trial. (1/81)
BACKGROUND: Although several early trials indicate treatment of restenosis with radiation therapy is safe and effective, the long-term impact of this new technology has been questioned. The objective of this report is to document angiographic and clinical outcome 3 years after treatment of restenotic stented coronary arteries with catheter-based (192)Ir. METHODS AND RESULTS: A double-blind, randomized trial compared (192)Ir with placebo sources in patients with previous restenosis after coronary angioplasty. Over a 9-month period, 55 patients were enrolled; 26 were randomized to (192)Ir and 29 to placebo. At 3-year follow-up, target-lesion revascularization was significantly lower in the (192)Ir group (15. 4% versus 48.3%; P<0.01). The dichotomous restenosis rate at 3-year follow-up was also significantly lower in (192)Ir patients (33% versus 64%; P<0.05). In a subgroup of patients with 3-year angiographic follow-up not subjected to target-lesion revascularization by the 6-month angiogram, the mean minimal luminal diameter between 6 months and 3 years decreased from 2.49+/-0.81 to 2.12+/-0.73 mm in (192)Ir patients but was unchanged in placebo patients. CONCLUSIONS: The early clinical benefits observed after treatment of coronary restenosis with (192)Ir appear durable at late follow-up. Angiographic restenosis continues to be significantly reduced in (192)Ir-treated patients, but a small amount of late loss was observed between the 6-month and 3-year follow-up time points. No events occurred in the (192)Ir group to suggest major untoward effects of vascular radiotherapy. At 3-year follow-up, vascular radiotherapy continues to be a promising new treatment for restenosis. (+info)Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. (2/81)
BACKGROUND: Although the frequency of restenosis after coronary angioplasty is reduced by stenting, when restenosis develops within a stent, the risk of subsequent restenosis is greater than 50 percent. We report on a multicenter, double-blind, randomized trial of intracoronary radiation therapy for the treatment of in-stent restenosis. METHODS: Of 252 eligible patients in whom in-stent restenosis had developed, 131 were randomly assigned to receive an indwelling intracoronary ribbon containing a sealed source of iridium-192, and 121 were assigned to receive a similar-appearing nonradioactive ribbon (placebo). RESULTS: The primary end point, a composite of death, myocardial infarction, and the need for repeated revascularization of the target lesion during nine months of follow-up, occurred in 53 patients assigned to placebo (43.8 percent) and 37 patients assigned to iridium-192 (28.2 percent, P=0.02). However, the reduction in the incidence of major adverse cardiac events was determined solely by a diminished need for revascularization of the target lesion, not by reductions in the incidence of death or myocardial infarction. Late thrombosis occurred in 5.3 percent of the iridium-192 group, as compared with 0.8 percent of the placebo group (P=0.07), resulting in more late myocardial infarctions in the iridium-192 group (9.9 percent vs. 4.1 percent, P=0.09). Late thrombosis occurred in irradiated patients only after the discontinuation of oral antiplatelet therapy (with ticlopidine or clopidogrel) and only in patients who had received new stents at the time of radiation treatment. CONCLUSIONS: Intracoronary irradiation with iridium-192 resulted in lower rates of clinical and angiographic restenosis, although it was also associated with a higher rate of late thrombosis, resulting in an increased risk of myocardial infarction. If the problem of late thrombosis within the stent can be overcome, intracoronary irradiation with iridium-192 may become a useful approach to the treatment of in-stent restenosis. (+info)Serial intravascular ultrasound analysis of the impact of lesion length on the efficacy of intracoronary gamma-irradiation for preventing recurrent in-stent restenosis. (3/81)
BACKGROUND: The relation between lesion length and effectiveness of brachytherapy is not well studied. METHODS AND RESULTS: We compared serial (postintervention and follow-up) intravascular ultrasound findings in 66 patients with native coronary artery in-stent restenosis (ISR) who were treated with (192)Ir (15 Gy delivered 2 mm away from the radiation source). Patients were enrolled in the Washington Radiation for In-Stent Restenosis Trial (WRIST; ISR length, 10 to 47 mm; n=36) or Long WRIST (ISR length, 36 to 80 mm; n=30). External elastic membrane, stent, lumen, and intimal hyperplasia (IH; stent minus lumen) areas and source-to-target (intravascular ultrasound catheter to external elastic membrane) distances were measured. Postintervention stent areas were larger in WRIST and smaller in Long WRIST patients (P:<0.0001). At follow-up, maximum IH area significantly increased in both WRIST and Long WRIST patients (P:<0.0001 for both), but this increase was greater in Long WRIST patients (P:=0.0006). Similarly, minimum lumen cross-sectional area significantly decreased in both WRIST and Long WRIST patients (P:<0.05 and P:<0.0001, respectively), but this decrease was more pronounced in Long WRIST patients (P:=0.0567). The maximum source-to-target distance was longer in Long WRIST than in WRIST, and it correlated directly with ISR length (r=0.547, P:<0.0001). Overall, the change in minimum lumen area and the change in maximum IH area correlated with the maximum source-to-target distance (r=0.352, P:=0.0038 and r=0.523, P:<0.0001 for WRIST and Long WRIST, respectively). The variability (maximum/minimum) in IH area at follow-up also correlated with the maximum source-to-target distance (r=0.378, P:<0.0001). CONCLUSIONS: Brachytherapy may be less effective in longer ISR lesions because of the greater variability and longer source-to-target distances in diffuse ISR. (+info)Edge stenosis and geographical miss following intracoronary gamma radiation therapy for in-stent restenosis. (4/81)
OBJECTIVES: We sought to determine the relationship between geographical miss (GM) and edge restenosis (ERS) following intracoronary radiation therapy. BACKGROUND: Edge restenosis may be a limitation of intracoronary irradiation to prevent in-stent restenosis (ISR). Inadequate radiation source coverage of the injured segment (GM) has been proposed as a cause of ERS. We studied the relationship between GM and ERS following 192Ir treatment of ISR. METHODS: There were 100 patients with native vessel ISR in WRIST (Washington Radiation for In-Stent Restenosis Trial), in which patients with ISR were first treated with conventional techniques and then randomized to gamma irradiation (192Ir) or placebo. Geographical miss was defined as segments proximal or distal to the treated lesion that were subjected to injury during primary intervention but were not covered by the radiation source. RESULTS: Geographical miss was documented in 56 of 164 edges (34%). Edge restenosis was noted at eight of 80 radiated edges and in four of 84 placebo edges. In the irradiated group, ERS was observed in 21% of edges with GM and in 40% of edges without GM (p = 0.035). In contrast, in the placebo group, ERS was observed in only 7% of edges with GM and in 4% of edges without GM (p = NS). The late edge lumen loss was higher in the irradiated group with GM as compared to placebo with GM (0.74 +/- 0.57 vs. 0.41 +/- 0.50 mm, p = 0.016). CONCLUSIONS: Edge restenosis following gamma irradiation treatment of ISR is related to GM: a mismatch between the segment of artery injured during the primary catheter-based intervention and the length of the radiation source. (+info)Interstitial brachytherapy using iridium-192 for malignant brain tumors: clinical results. (5/81)
OBJECTIVE: To determine the effects and toxicity of interstitial brachytherapy using iridium-192 on brain malignant gliomas. METHODS: Between January 1992 and January 1995, 56 patients with anaplastic astrocytoma and glioblastoma multiforme were treated with stereotactic brachytherapy using temporary high-activity iridium-192 sources. RESULTS: The median survival for patients receiving brachytherapy was 28 months. The survival rates at 1, 2, 3 years were 92.8%, 83.9% and 71.4% respectively. CONCLUSIONS: Brachytherapy may improve the control of local tumor and prolong the survival, when used in deep malignant brain gliomas, by temporary implanted high doses of iridium-192 sources. (+info)192Ir endovascular irradiation prevents restenosis after balloon angioplasty in rabbit. (6/81)
OBJECTIVE: To examine the effect of endovascular irradiation on restenosis after balloon angioplasty in rabbit. METHODS: After the establishment of rabbit iliac atherosclerosis model, balloon angioplasty was performed at the lesion segment of the iliac artery. Rabbits were randomly divided into three groups: control group, 10 Gy irradiated group and 18 Gy irradiated group. Endovascular irradiation was performed for irradiated groups at the dilated sites by introducing the 192Ir radioactive guidewire through a catheter. After four weeks, the animals were killed and the target segments were cut down. Histopathologic and morphometric analyses were carried out. RESULTS: The mean final lumen area in the 18 Gy group was larger than that in the control or 10 Gy group (P < 0.05). The intimal area in the 18 Gy group was smaller (P < 0.05). CONCLUSIONS: 192Ir endovascular irradiation may prevent restenosis after balloon angioplasty. The effect is related to the delivered dose. The mechanism is involved in inhibition of neointimal proliferation. (+info)Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. (7/81)
OBJECTIVES: The study was done to investigate the relationship between clinical restenosis and the relative angiographic location of the recurrent restenotic lesion, after treatment of in-stent restenosis with vascular brachytherapy in the Washington Radiation for In-Stent Restenosis Trial (WRIST). BACKGROUND: Intracoronary radiation therapy reduces recurrence of in-stent restenosis. We investigated the above objective in patients enrolled in WRIST. METHODS: The WRIST study randomized 130 patients to double-blinded therapy with gamma irradiation (iridium-192 [(192)Ir]) versus placebo after interventional treatment of diffuse in-stent restenosis. After the intervention and at follow-up, three vessel segments were individually analyzed with quantitative coronary angiography: 1) the "stent," 2) the "radiation ribbon," and 3) the "ribbon+margin" segment (including 5 mm on either end of the injured or radiation-ribbon segment). Receiver operator curves (ROC) were used to assess the value of the follow-up percent diameter stenosis (DS) for each of the three analyzed segments in predicting target vessel revascularization (TVR). RESULTS: (192)Ir reduced recurrent restenosis (23.7% vs. 60.7%, p < 0.001) and the length of recurrent restenosis (8.99 +/- 4.34 mm vs. 17.54 +/- 10.48 mm, p < 0.001) at follow-up compared to placebo. Isolated stent edge (3.4%) and ribbon edge (1.7%) restenoses were infrequent in both groups. The best angiographic surrogate of TVR was the 50% follow-up DS obtained from the ribbon+margin analysis (ROC area 0.806). CONCLUSIONS: In WRIST, not only was (192)Ir therapy effective in reducing restenosis, but it also reduced the lesion length of treatment failures by 50%, and it was not associated with edge proliferation. The restenosis rate obtained from the vessel segment inclusive of the dose fall-off zones was the best correlate of TVR and should become a standard analysis site in all vascular brachytherapy trials. (+info)High-dose-rate brachytherapy in the treatment of carcinoma of the prostate. (8/81)
BACKGROUND: Although radical prostatectomy for localized disease is considered as a standard of care, external-beam radiotherapy and brachytherapy are equally effective. We report on the technique and preliminary results of high-dose-rate (HDR) brachytherapy using a temporary iridium-192 implant technique. METHODS: The authors reviewed the literature on the techniques, treatment protocols, and results of HDR brachytherapy in the treatment of carcinoma of the prostate, and they report their own protocols, technique, and results. RESULTS: The combination of HDR brachytherapy and external irradiation has been well tolerated by all 200 patients in our series, with less than 3% grade 3 late complications and with 95% PSA relapse-free survival with a median follow-up of 24 months. CONCLUSIONS: HDR brachytherapy may be the most conformal type of irradiation in the treatment of carcinoma of the prostate regardless of tumor size, anatomical distortion, and organ mobility. (+info)Iridium is not a medical term, but rather a chemical element with the symbol Ir and atomic number 77. It's a transition metal that is part of the platinum group. Iridium has no known biological role in humans or other organisms, and it is not used in medical treatments or diagnoses.
However, iridium is sometimes mentioned in the context of geological time scales because iridium-rich layers in rock formations are associated with major extinction events, such as the one that marked the end of the Cretaceous period 65 million years ago. The leading hypothesis for this association is that large asteroid impacts can create iridium-rich vapor plumes that settle onto the Earth's surface and leave a distinct layer in the rock record.
Iridium radioisotopes are unstable isotopes or variants of the element iridium that emit radiation as they decay into more stable forms. These isotopes can be used in various medical applications, such as brachytherapy, a type of cancer treatment where a small amount of radioactive material is placed inside the body near the tumor site to deliver targeted radiation therapy.
Iridium-192 is one commonly used iridium radioisotope for this purpose. It has a half-life of 74.2 days and emits gamma rays, making it useful for treating various types of cancer, including breast, gynecological, prostate, and head and neck cancers.
It's important to note that handling and using radioisotopes requires specialized training and equipment due to the potential radiation hazards associated with them.
Radioisotopes, also known as radioactive isotopes or radionuclides, are variants of chemical elements that have unstable nuclei and emit radiation in the form of alpha particles, beta particles, gamma rays, or conversion electrons. These isotopes are formed when an element's nucleus undergoes natural or artificial radioactive decay.
Radioisotopes can be produced through various processes, including nuclear fission, nuclear fusion, and particle bombardment in a cyclotron or other types of particle accelerators. They have a wide range of applications in medicine, industry, agriculture, research, and energy production. In the medical field, radioisotopes are used for diagnostic imaging, radiation therapy, and in the labeling of molecules for research purposes.
It is important to note that handling and using radioisotopes requires proper training, safety measures, and regulatory compliance due to their ionizing radiation properties, which can pose potential health risks if not handled correctly.
Zinc radioisotopes are unstable isotopes or variants of the element zinc that undergo radioactive decay, emitting radiation in the process. These isotopes have a different number of neutrons than the stable isotope of zinc (zinc-64), which contributes to their instability and tendency to decay.
Examples of zinc radioisotopes include zinc-65, zinc-70, and zinc-72. These isotopes are often used in medical research and diagnostic procedures due to their ability to emit gamma rays or positrons, which can be detected using specialized equipment.
Zinc radioisotopes may be used as tracers to study the metabolism and distribution of zinc in the body, or as therapeutic agents to deliver targeted radiation therapy to cancer cells. However, it is important to note that the use of radioisotopes carries potential risks, including exposure to ionizing radiation and the potential for damage to healthy tissues.
Hydrogenation, in the context of food science and biochemistry, refers to the process of adding hydrogen atoms to certain unsaturated fats or oils, converting them into saturated fats. This is typically done through a chemical reaction using hydrogen gas in the presence of a catalyst, often a metal such as nickel or palladium.
The process of hydrogenation increases the stability and shelf life of fats and oils, but it can also lead to the formation of trans fats, which have been linked to various health issues, including heart disease. Therefore, the use of partially hydrogenated oils has been largely phased out in many countries.
Allyl compounds are organic compounds that contain the allyl group, which is a functional group with the formula CH2=CH-CH2-. The allyl group consists of a methylene bridge (CH2-) flanked by a carbon-carbon double bond (-CH=). Allyl compounds can be derived from allyl alcohol, allyl chloride, or other allyl halides and can participate in various chemical reactions due to the reactivity of the double bond. They are used in organic synthesis, pharmaceuticals, and agrochemicals.
Coordination complexes are chemical compounds in which a central metal atom or ion is bonded to one or more ligands (molecules or ions that donate a pair of electrons to form a coordinate covalent bond) through a coordination number, which refers to the number of individual bonds formed between the metal and the ligands.
The structure and properties of coordination complexes are determined by the type of metal ion, the nature and number of ligands, and the geometry of the coordination sphere around the metal ion. These complexes have important applications in various fields such as catalysis, bioinorganic chemistry, materials science, and medicinal chemistry.
The formation of coordination complexes can be described by the following reaction:
M + nL ↔ MLn
Where M is the metal ion, L is the ligand, and n is the number of ligands bonded to the metal ion. The double arrow indicates that the reaction can proceed in both directions, with the equilibrium favoring either the formation or dissociation of the complex depending on various factors such as temperature, pressure, and concentration.
The study of coordination complexes is an important area of inorganic chemistry, and it involves understanding the electronic structure, bonding, and reactivity of these compounds. The use of crystal field theory and molecular orbital theory provides a framework for describing the behavior of coordination complexes and predicting their properties.
I'm sorry for any confusion, but the term "minor planets" is not typically used in medical definitions. It is a term from astronomy that refers to small celestial bodies orbiting the Sun, which are smaller than planets and dwarf planets. They are also commonly known as asteroids. If you have any questions related to medical terminology or health concerns, I would be happy to help with those instead!
The Radioisotope Dilution Technique is a method used in nuclear medicine to measure the volume and flow rate of a particular fluid in the body. It involves introducing a known amount of a radioactive isotope, or radioisotope, into the fluid, such as blood. The isotope mixes with the fluid, and samples are then taken from the fluid at various time points.
By measuring the concentration of the radioisotope in each sample, it is possible to calculate the total volume of the fluid based on the amount of the isotope introduced and the dilution factor. The flow rate can also be calculated by measuring the concentration of the isotope over time and using the formula:
Flow rate = Volume/Time
This technique is commonly used in medical research and clinical settings to measure cardiac output, cerebral blood flow, and renal function, among other applications. It is a safe and reliable method that has been widely used for many years. However, it does require the use of radioactive materials and specialized equipment, so it should only be performed by trained medical professionals in appropriate facilities.
I'm sorry for any confusion, but "meteoroids" is not a term used in medical definitions. It is a term from the field of astronomy. Meteoroids are small particles or bits of rock that are traveling in space. When they enter the Earth's atmosphere, they can become meteors (also known as "shooting stars") and can sometimes make it to the ground as meteorites.
Phosphines are a class of organic compounds characterized by a phosphorus atom bonded to three organic groups and a hydrogen atom, with the general formula of PRR'R''H. They are important in various chemical reactions as reducing agents and catalysts. In medicine, phosphines have no direct medical application. However, certain phosphine compounds have been studied for their potential use as pharmaceuticals, such as phosphinic acids which have shown promise as protease inhibitors used in the treatment of diseases like HIV and HCV. It is important to note that some phosphines are highly toxic and should be handled with care.
Strontium radioisotopes are radioactive isotopes of the element strontium. Strontium is an alkaline earth metal that is found in nature and has several isotopes, some of which are stable and some of which are radioactive. The radioactive isotopes of strontium, also known as strontium radionuclides, decay and emit radiation in the form of beta particles.
Strontium-89 (^89Sr) and strontium-90 (^90Sr) are two common radioisotopes of strontium that are used in medical applications. Strontium-89 is a pure beta emitter with a half-life of 50.5 days, which makes it useful for the treatment of bone pain associated with metastatic cancer. When administered, strontium-89 is taken up by bones and irradiates the bone tissue, reducing pain and improving quality of life in some patients.
Strontium-90, on the other hand, has a longer half-life of 28.8 years and emits more powerful beta particles than strontium-89. It is used as a component in radioactive waste and in some nuclear weapons, but it is not used in medical applications due to its long half-life and high radiation dose.
It's important to note that exposure to strontium radioisotopes can be harmful to human health, especially if ingested or inhaled. Therefore, handling and disposal of strontium radioisotopes require special precautions and regulations.
In chemistry, an alcohol is a broad term that refers to any organic compound characterized by the presence of a hydroxyl (-OH) functional group attached to a carbon atom. This means that alcohols are essentially hydrocarbons with a hydroxyl group. The simplest alcohol is methanol (CH3OH), and ethanol (C2H5OH), also known as ethyl alcohol, is the type of alcohol found in alcoholic beverages.
In the context of medical definitions, alcohol primarily refers to ethanol, which has significant effects on the human body when consumed. Ethanol can act as a central nervous system depressant, leading to various physiological and psychological changes depending on the dose and frequency of consumption. Excessive or prolonged use of ethanol can result in various health issues, including addiction, liver disease, neurological damage, and increased risk of injuries due to impaired judgment and motor skills.
It is important to note that there are other types of alcohols (e.g., methanol, isopropyl alcohol) with different chemical structures and properties, but they are not typically consumed by humans and can be toxic or even lethal in high concentrations.
I'm sorry for any confusion, but "Rhodium" is not a medical term. It is a chemical element with the symbol Rh and atomic number 45. It is a rare, silvery-white, hard, corrosion-resistant, and chemically inert transition metal. It is found in small quantities in platinum or nickel ores along with some other rare metals.
It's primarily used in industrial applications, such as being a key component in catalytic converters in automobiles, which helps to reduce harmful emissions. It's also used in jewelry, electronics, and scientific instruments due to its properties of resistance to corrosion and heat.
If you have any medical terms or concepts that you would like me to explain, please let me know!
Iodine radioisotopes are radioactive isotopes of the element iodine, which decays and emits radiation in the form of gamma rays. Some commonly used iodine radioisotopes include I-123, I-125, I-131. These radioisotopes have various medical applications such as in diagnostic imaging, therapy for thyroid disorders, and cancer treatment.
For example, I-131 is commonly used to treat hyperthyroidism and differentiated thyroid cancer due to its ability to destroy thyroid tissue. On the other hand, I-123 is often used in nuclear medicine scans of the thyroid gland because it emits gamma rays that can be detected by a gamma camera, allowing for detailed images of the gland's structure and function.
It is important to note that handling and administering radioisotopes require specialized training and safety precautions due to their radiation-emitting properties.
Krypton is a noble gas with the symbol Kr and atomic number 36. It exists in various radioisotopes, which are unstable isotopes of krypton that undergo radioactive decay. A few examples include:
1. Krypton-81: This radioisotope has a half-life of about 2.1 x 10^5 years and decays via electron capture to rubidium-81. It is produced naturally in the atmosphere by cosmic rays.
2. Krypton-83: With a half-life of approximately 85.7 days, this radioisotope decays via beta decay to bromine-83. It can be used in medical imaging for lung ventilation studies.
3. Krypton-85: This radioisotope has a half-life of about 10.7 years and decays via beta decay to rubidium-85. It is produced as a byproduct of nuclear fission and can be found in trace amounts in the atmosphere.
4. Krypton-87: With a half-life of approximately 76.3 minutes, this radioisotope decays via beta decay to rubidium-87. It is not found naturally on Earth but can be produced artificially.
It's important to note that while krypton radioisotopes have medical applications, they are also associated with potential health risks due to their radioactivity. Proper handling and safety precautions must be taken when working with these substances.